SCHEMBL7378944

SCHEMBL7378944

COC(=O)CCCc1ccnc2ncccc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ LMNA P02545 1/20 0.43
▸ CHRM1 P11229 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ GSK3A P49840 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ TBXAS1 P24557 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7992922 0.82 MEN1 (0.48) ALDH1A1SMN1; SMN2CHRM1KMT2ACYP1A2
SCHEMBL2878520 0.77 NUDT1 (0.48) ALDH1A1MAPTHPGDSMN1; SMN2CYP1A2
SCHEMBL4059940 0.75 KDM4E (0.50) ALDH1A1MAPTHPGDSMN1; SMN2CYP1A2
SCHEMBL28309323 0.74 ALDH1A1 (0.57) ALDH1A1MAPTHPGDCYP1A2CYP2C19
SCHEMBL7381057 0.73 MC4R (0.41) ALDH1A1MAPTSMN1; SMN2LMNAKMT2A
SCHEMBL17537545 0.72 ALDH1A1 (0.54) ALDH1A1MAPTHPGDLMNAKMT2A
SCHEMBL12844167 0.72 GRM5 (0.40) ALDH1A1MAPTHPGDLMNAGSK3A
SCHEMBL3142657 0.72 KDM4E (0.41) ALDH1A1MAPTHPGDSMN1; SMN2LMNA
SCHEMBL18163286 0.72 SMN1; SMN2 (0.60) ALDH1A1MAPTSMN1; SMN2LMNAKMT2A
SCHEMBL8372588 0.71 GSK3A (0.40) ALDH1A1MAPTSMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294549-B1 COMPOUNDS USEFUL FOR INHIBITING RESTENOSIS, ANGIOGENESIS, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, INFLAMMATION OR TUMOR GROWTH. MERCK & CO., INC. 2001-09-25 — — US disclosed
US-5952306-A INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES MERCK & CO., INC. (US) 1999-09-14 — — US disclosed
EP-0880511-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-06-16 — — EP disclosed
EP-0880511-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-12-02 — — EP disclosed
WO-1997026250-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-07-24 — — WO disclosed
Send feedback